X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-03-02 | ABBV | Abbvie Inc. | Siatis Perry C | EVP, GC, SECRETARY | S - Sale | $234.39 | -18,668 | 4,619 | -80% | -$4,375,549 | ||||||
2026-03-03 | ANIP | Ani Pharmaceuticals Inc | Walsh Patrick D | Dir | S - Sale | $74.23 | -6,000 | 52,405 | -10% | -$445,380 | ||||||
| M | 2026-03-02 | BHC | Bausch Health Companies Inc. | Carson Seana | EVP, GC | S - Sale | $5.78 | -11,276 | 616,761 | -2% | -$65,131 | |||||
| M | 2026-02-27 | AUPH | Aurinia Pharmaceuticals Inc. | Tang Kevin | Dir | P - Purchase | $14.10 | +900,000 | 12,229,500 | +8% | +$12,688,806 | |||||
2026-02-27 | NGNE | Neurogene Inc. | Cvijic Christine Mikail | Pres, CFO | S - Sale | $25.11 | -4,800 | 109,843 | -4% | -$120,526 | ||||||
2026-03-02 | EDSA | Edesa Biotech, Inc. | Nijhawan Pardeep | CEO, 10% | P - Purchase | $2.09 | +3,000 | 1,118,241 | 0% | +$6,280 | ||||||
| D | 2026-03-02 | BIOA | Bioage Labs, Inc. | Rubin Paul D | Chief Medical Officer | S - Sale+OE | $20.30 | -7,433 | 0 | -100% | -$150,890 | |||||
| D | 2026-03-02 | LQDA | Liquidia Corp | Schundler Russell | GC | S - Sale+OE | $30.58 | -1,073 | 628,557 | 0% | -$32,812 | |||||
2026-02-27 | VRTX | Vertex Pharmaceuticals Inc / Ma | Kewalramani Reshma | CEO, Pres | S - Sale | $493.47 | -40,000 | 98,278 | -29% | -$19,738,855 | ||||||
| D | 2026-03-02 | LQDA | Liquidia Corp | Moomaw Scott | Chief Commercial Officer | S - Sale+OE | $30.58 | -827 | 188,954 | 0% | -$25,290 | |||||
2026-03-02 | LQDA | Liquidia Corp | Krepp Sarah | Chief Human Resource Officer | S - Sale | $30.58 | -276 | 164,658 | 0% | -$8,440 | ||||||
| D | 2026-03-02 | LQDA | Liquidia Corp | Kaseta Michael | CFO, COO | S - Sale+OE | $30.58 | -1,165 | 411,855 | 0% | -$35,626 | |||||
| D | 2026-03-02 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $515.37 | -9,500 | 639,489 | -1% | -$4,896,019 | |||||
2026-03-02 | LQDA | Liquidia Corp | Boyle Dana | Chief Accounting Officer | S - Sale | $30.58 | -445 | 178,840 | 0% | -$13,608 | ||||||
| D | 2026-03-02 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale+OE | $30.58 | -689 | 212,479 | 0% | -$21,070 | |||||
2026-03-02 | KPTI | Karyopharm Therapeutics Inc. | Mano Michael | EVP, CLO, Secretary | S - Sale | $9.41 | -3,526 | 93,964 | -4% | -$33,178 | ||||||
2026-03-02 | KPTI | Karyopharm Therapeutics Inc. | Rangwala Reshma | EVP, Chief Medical Officer | S - Sale | $9.41 | -5,066 | 56,739 | -8% | -$47,669 | ||||||
2026-02-27 | VRTX | Vertex Pharmaceuticals Inc / Ma | Bozic Carmen | EVP, CMO | S - Sale | $480.31 | -2,329 | 37,734 | -6% | -$1,118,642 | ||||||
| D | 2026-02-27 | JNJ | Johnson & Johnson | Decker Robert J | VP Corporate Controller | S - Sale+OE | $247.87 | -4,075 | 24,462 | -14% | -$1,010,070 | |||||
2026-03-02 | KPTI | Karyopharm Therapeutics Inc. | Paulson Richard A. | Pres, CEO | S - Sale | $9.41 | -12,361 | 267,030 | -4% | -$116,311 | ||||||
| D | 2026-03-02 | AGIO | Agios Pharmaceuticals, Inc. | Goff Brian | CEO | S - Sale+OE | $28.96 | -18,055 | 164,548 | -10% | -$522,873 | |||||
| D | 2026-02-27 | BBIO | Bridgebio Pharma, Inc. | Valantine Hannah | Dir | S - Sale+OE | $67.41 | -25,484 | 7,863 | -76% | -$1,717,781 | |||||
| D | 2026-03-02 | AGIO | Agios Pharmaceuticals, Inc. | Burns James William | GC | S - Sale+OE | $28.96 | -5,218 | 44,086 | -11% | -$151,113 | |||||
| D | 2026-03-02 | AGIO | Agios Pharmaceuticals, Inc. | Gheuens Sarah | Chief Medical Officer | S - Sale+OE | $28.96 | -4,055 | 74,406 | -5% | -$117,433 | |||||
| D | 2026-03-02 | AGIO | Agios Pharmaceuticals, Inc. | Jones Cecilia | CFO | S - Sale+OE | $28.96 | -5,035 | 49,328 | -9% | -$145,814 | |||||
| D | 2026-03-02 | AGIO | Agios Pharmaceuticals, Inc. | Milanova Tsveta | Chief Commercial Officer | S - Sale+OE | $28.96 | -2,868 | 41,591 | -6% | -$83,057 | |||||
2026-02-27 | HROW | Harrow, Inc. | Opaleye Management Inc. | 10% | S - Sale | $54.18 | -5,000 | 3,880,000 | 0% | -$270,900 | ||||||
2026-03-02 | REGN | Regeneron Pharmaceuticals, Inc. | Ryan Arthur F | Dir | S - Sale | $785.50 | -100 | 17,703 | -1% | -$78,550 | ||||||
2026-03-02 | FBLG | Fibrobiologics, Inc. | Davis Jason | CFO | P - Purchase | $0.41 | +70,000 | 70,000 | New | +$28,973 | ||||||
2026-02-27 | ARVN | Arvinas, Inc. | Houston John G | Dir | S - Sale | $13.21 | -35,297 | 1,122,183 | -3% | -$466,154 | ||||||
2026-02-27 | LRMR | Larimar Therapeutics, Inc. | Flynn James E | * Director by Deputization, 10% | P - Purchase | $5.00 | +5,000,000 | 35,606,974 | +16% | +$25,000,000 | ||||||
2026-03-02 | IDYA | Ideaya Biosciences, Inc. | Stein Jeffrey | Dir | P - Purchase | $32.96 | +50,000 | 61,007 | +454% | +$1,647,890 | ||||||
2026-03-02 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale | $15.44 | -8,148 | 34,601 | -19% | -$125,793 | ||||||
| D | 2026-03-02 | ORKA | Oruka Therapeutics, Inc. | Sandler Laura Lee | COO | S - Sale+OE | $33.56 | -5,000 | 237,584 | -2% | -$167,822 | |||||
| M | 2026-02-26 | LFVN | Lifevantage Corp | Dayton Judd | Dir | P - Purchase | $4.59 | +33,197 | 829,684 | +4% | +$152,422 | |||||
2026-03-02 | CTNM | Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | S - Sale | $15.01 | -4,170 | 158,724 | -3% | -$62,585 | ||||||
| D | 2026-03-02 | CTNM | Contineum Therapeutics, Inc. | Watkins Tim | CMO, Head of Development | S - Sale+OE | $15.02 | -3,611 | 0 | -100% | -$54,220 | |||||
| D | 2026-03-02 | NAMS | Newamsterdam Pharma Co N.V. | Davidson Michael H. | CEO | S - Sale+OE | $33.25 | -443,707 | 174,144 | -72% | -$14,753,258 | |||||
| D | 2026-03-02 | GENB | Generate Biomedicines, Inc. | Grous Beth | Chief People Officer | P - Purchase | $16.00 | +300 | 300 | New | +$4,800 | |||||
| D | 2026-03-02 | GENB | Generate Biomedicines, Inc. | Silvers Jason | Pres, CFO | P - Purchase | $16.00 | +2,000 | 1,500 | -400% | +$32,000 | |||||
| D | 2026-03-02 | GENB | Generate Biomedicines, Inc. | Afeyan Noubar | Dir, 10% | P - Purchase | $16.00 | +4,687,500 | 62,673,117 | +8% | +$75,000,000 | |||||
| D | 2026-03-02 | GENB | Generate Biomedicines, Inc. | Mendillo Jane L | Dir | P - Purchase | $16.00 | +1,500 | 1,500 | New | +$24,000 | |||||
| D | 2026-03-02 | GENB | Generate Biomedicines, Inc. | Afeyan Noubar | Dir, 10% | P - Purchase | $16.00 | +4,687,500 | 62,673,117 | +8% | +$75,000,000 | |||||
| D | 2026-02-27 | JAZZ | Jazz Pharmaceuticals Plc | Riedel Norbert G | Dir | S - Sale+OE | $192.00 | -3,415 | 17,654 | -16% | -$655,680 | |||||
2026-03-02 | MDGL | Madrigal Pharmaceuticals, Inc. | Dier Mardi | EVP, CFO | S - Sale | $427.21 | -1,183 | 9,257 | -11% | -$505,389 | ||||||
| M | 2026-02-26 | JAZZ | Jazz Pharmaceuticals Plc | Carr Patricia | SVP, Chief Accounting Officer | S - Sale | $192.60 | -2,370 | 9,235 | -20% | -$456,466 | |||||
| D | 2026-02-26 | JAZZ | Jazz Pharmaceuticals Plc | Patil Neena M | EVP, GC | S - Sale+OE | $191.56 | -55,600 | 58,818 | -49% | -$10,650,482 | |||||
| M | 2026-02-26 | EDSA | Edesa Biotech, Inc. | Nijhawan Pardeep | CEO, 10% | P - Purchase | $1.96 | +50,571 | 1,115,241 | +5% | +$99,176 | |||||
2026-02-26 | JAZZ | Jazz Pharmaceuticals Plc | Henderson Mary Elizabeth | SVP, Technical Operations | S - Sale | $194.49 | -5,343 | 28,728 | -16% | -$1,039,134 | ||||||
| D | 2026-02-26 | NUVL | Nuvalent, Inc. | Noci Darlene | Chief Development Officer | S - Sale+OE | $103.03 | -5,500 | 58,117 | -9% | -$566,682 | |||||
| D | 2026-02-26 | NUVL | Nuvalent, Inc. | Miller Deborah Ann | GC | S - Sale+OE | $103.05 | -5,500 | 59,634 | -8% | -$566,788 | |||||
2026-02-27 | UTHR | United Therapeutics Corp | Olian Judy D. | Dir | S - Sale | $509.55 | -200 | 4,845 | -4% | -$101,910 | ||||||
2026-02-27 | LRMR | Larimar Therapeutics, Inc. | Hamilton Thomas Edward | Dir | P - Purchase | $5.00 | +100,000 | 824,231 | +14% | +$500,000 | ||||||
2026-02-27 | LRMR | Larimar Therapeutics, Inc. | Thomas Frank E | Dir | P - Purchase | $5.00 | +5,000 | 7,000 | +250% | +$25,000 | ||||||
| D | 2026-02-23 | OVID | Ovid Therapeutics Inc. | Alexander Margaret A. | Pres, CEO | S - Sale+OE | $1.45 | -11,656 | 61,750 | -16% | -$16,901 | |||||
2026-02-27 | LRMR | Larimar Therapeutics, Inc. | Sherman Jeffrey W | Dir | P - Purchase | $5.00 | +5,000 | 5,000 | New | +$25,000 | ||||||
| D | 2026-02-23 | OVID | Ovid Therapeutics Inc. | Rona Jeffrey A | CBFO | S - Sale+OE | $1.45 | -8,541 | 156,313 | -5% | -$12,384 | |||||
2026-03-02 | CYTK | Cytokinetics Inc | Parshall B Lynne | Dir | S - Sale | $61.21 | -5,000 | 17,933 | -22% | -$306,050 | ||||||
| D | 2026-03-02 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale+OE | $61.62 | -886 | 50,440 | -2% | -$54,595 | |||||
| D | 2026-02-26 | BCAX | Bicara Therapeutics Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $16.00 | +300,000 | 7,255,993 | +4% | +$4,800,000 | |||||
2026-02-26 | VRTX | Vertex Pharmaceuticals Inc / Ma | Ambrose Kristen | SVP, Chief Accounting Officer | S - Sale | $483.36 | -357 | 6,624 | -5% | -$172,560 | ||||||
| D | 2026-02-27 | ALNY | Alnylam Pharmaceuticals, Inc. | Garg Pushkal | EVP Chief R, D | S - Sale+OE | $331.34 | -4,627 | 22,810 | -17% | -$1,533,100 | |||||
2026-02-26 | TEVA | Teva Pharmaceutical Industries Ltd | Kalif Eliyahu Sharon | EVP, CFO | S - Sale | $33.64 | -345,810 | 57,478 | -86% | -$11,634,708 | ||||||
2026-02-27 | ABCL | Abcellera Biologics Inc. | Thermopylae Holdings Ltd. | 10% | P - Purchase | $3.44 | +38,000 | 56,134,097 | 0% | +$130,720 | ||||||
2026-02-27 | FBLG | Fibrobiologics, Inc. | Garcia Ruben A | GC | P - Purchase | $0.33 | +40,000 | 180,000 | +29% | +$13,056 | ||||||
2026-02-27 | PVLA | Palvella Therapeutics, Inc. | Jenkins George M | Dir | P - Purchase | $125.00 | +4,000 | 200,687 | +2% | +$500,000 | ||||||
2026-02-27 | PVLA | Palvella Therapeutics, Inc. | Heron Elaine J | Dir | P - Purchase | $125.00 | +2,400 | 53,691 | +5% | +$300,000 | ||||||
| D | 2026-02-26 | WVE | Wave Life Sciences Ltd. | Francis Chris | See Remarks | S - Sale+OE | $15.05 | -33,194 | 61,867 | -35% | -$499,593 | |||||
2026-02-25 | QTTB | Q32 Bio Inc. | Kalowski Lee | CFO, Pres | S - Sale | $4.51 | -3,995 | 35,943 | -10% | -$18,035 | ||||||
2026-02-26 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Dir | S - Sale | $161.11 | -25,000 | 450,996 | -5% | -$4,027,750 | ||||||
| D | 2026-02-26 | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | COO | S - Sale+OE | $161.88 | -35,378 | 0 | -100% | -$5,726,991 | |||||
2026-02-25 | QTTB | Q32 Bio Inc. | Morrison Jodie Pope | CEO | S - Sale | $4.51 | -9,896 | 89,104 | -10% | -$44,675 | ||||||
2026-02-25 | QTTB | Q32 Bio Inc. | Violette Shelia M. | Chief Scientific Officer | S - Sale | $4.51 | -2,815 | 91,846 | -3% | -$12,708 | ||||||
2026-02-25 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Pres, R, D | S - Sale | $12.77 | -54,345 | 132,873 | -29% | -$694,208 | ||||||
2026-02-27 | BHC | Bausch Health Companies Inc. | Carson Seana | EVP, GC | S - Sale | $5.95 | -8,388 | 809,258 | -1% | -$49,909 | ||||||
| D | 2026-02-25 | ABBV | Abbvie Inc. | Siatis Perry C | EVP, GC, SECRETARY | S - Sale+OE | $230.00 | -22,381 | 38,137 | -37% | -$5,147,630 | |||||
2026-02-25 | QURE | Uniqure N.V. | Kapusta Matthew C | CEO, MD | S - Sale | $23.86 | -12,378 | 639,076 | -2% | -$295,339 | ||||||
2026-02-25 | IRON | Disc Medicine, Inc. | Franchi Jean M. | CFO | S - Sale | $69.06 | -353 | 70,990 | 0% | -$24,377 | ||||||
| A | 2026-02-05 | MANE | Veradermics, Inc | Childs John W | Dir | P - Purchase | $17.00 | +294,117 | 294,117 | New | +$4,999,989 | |||||
2026-02-25 | QURE | Uniqure N.V. | Klemt Christian | CFO | S - Sale | $23.86 | -6,217 | 211,513 | -3% | -$148,338 | ||||||
2026-02-26 | ABCL | Abcellera Biologics Inc. | Thermopylae Holdings Ltd. | 10% | P - Purchase | $3.27 | +177,457 | 56,096,097 | 0% | +$580,284 | ||||||
| D | 2026-02-25 | BCAX | Bicara Therapeutics Inc. | Cohlhepp Ryan | Pres, COO | S - Sale+OE | $18.04 | -3,631 | 209,641 | -2% | -$65,501 | |||||
2026-02-26 | BBIO | Bridgebio Pharma, Inc. | Apuli Maricel | Chief Accounting Officer | S - Sale | $66.00 | -2,000 | 121,945 | -2% | -$132,000 | ||||||
| M | 2026-02-25 | CLYM | Climb Bio, Inc. | Thomas Stephen Basil | Dir | S - Sale | $7.01 | -50,000 | 154,657 | -24% | -$350,253 | |||||
2026-02-27 | ABCL | Abcellera Biologics Inc. | Booth Andrew | CFO | P - Purchase | $3.42 | +42,600 | 326,559 | +15% | +$145,692 | ||||||
2026-02-25 | LXRX | Lexicon Pharmaceuticals, Inc. | Debbane Raymond | Dir | P - Purchase | $1.49 | +2,000 | 51,660,909 | 0% | +$2,980 | ||||||
| DM | 2026-02-24 | NAMS | Newamsterdam Pharma Co N.V. | Davidson Michael H. | CEO | S - Sale+OE | $34.53 | -306,293 | 459,859 | -40% | -$10,575,091 | |||||
2026-02-26 | BMRN | Biomarin Pharmaceutical Inc | Friberg Gregory R | EVP, Chief R, D Officer | S - Sale | $60.38 | -6,326 | 37,578 | -14% | -$381,937 | ||||||
2026-02-26 | BMRN | Biomarin Pharmaceutical Inc | Davis George Eric | EVP, GC | S - Sale | $61.36 | -26,061 | 72,453 | -26% | -$1,599,103 | ||||||
| M | 2026-02-24 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale | $52.27 | -21,120 | 18,320 | -54% | -$1,103,938 | |||||
2026-02-25 | VRTX | Vertex Pharmaceuticals Inc / Ma | Tatsis Ourania | EVP, Chief Reg., Quality Offic | S - Sale | $486.35 | -260 | 46,763 | -1% | -$126,451 | ||||||
2026-02-25 | VRTX | Vertex Pharmaceuticals Inc / Ma | Sachdev Amit | EVP Chief Patient, Ext Af Off | S - Sale | $486.35 | -1,846 | 65,753 | -3% | -$897,802 | ||||||
2026-02-25 | VRTX | Vertex Pharmaceuticals Inc / Ma | McKechnie Duncan | EVP, Chief Commercial Officer | S - Sale | $487.65 | -4,910 | 17,559 | -22% | -$2,394,365 | ||||||
2026-02-25 | VRTX | Vertex Pharmaceuticals Inc / Ma | Bunnage Mark E. | EVP, Chief Scientific Officer | S - Sale | $486.35 | -620 | 7,284 | -8% | -$301,537 | ||||||
2026-02-25 | VRTX | Vertex Pharmaceuticals Inc / Ma | Biller Jonathan | EVP, GC | S - Sale | $486.35 | -945 | 13,659 | -6% | -$459,601 | ||||||
2026-02-25 | VRTX | Vertex Pharmaceuticals Inc / Ma | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Offi | S - Sale | $486.35 | -668 | 18,432 | -3% | -$324,882 | ||||||
2026-02-25 | VRTX | Vertex Pharmaceuticals Inc / Ma | Ambrose Kristen | SVP, Chief Accounting Officer | S - Sale | $486.35 | -223 | 6,981 | -3% | -$108,456 | ||||||
| D | 2026-02-24 | ORIC | Oric Pharmaceuticals, Inc. | Piscitelli Dominic | CFO | S - Sale+OE | $13.51 | -52,000 | 68,148 | -43% | -$702,686 | |||||
| DM | 2026-02-24 | CTNM | Contineum Therapeutics, Inc. | Stengone Carmine N. | CEO, Pres | S - Sale+OE | $16.02 | -7,100 | 14,954 | -32% | -$113,728 | |||||
| DM | 2026-02-24 | CTNM | Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | S - Sale+OE | $16.02 | -8,124 | 162,894 | -5% | -$130,164 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |